MTOR and malignant peripheral nerve sheath tumor: In addition to activating MEK, the loss of NF1 also activates the mammalian target of rapamycin (mTOR) in a Ras- and P13K-dependent manner to support MPNST pathogenesis [56,57] (see Figure 2).